Efficacy of dupilumab in atopic comorbidities associated with moderate‐to‐severe adult atopic dermatitis
- 23 April 2020
- Vol. 75 (10), 2653-2661
- https://doi.org/10.1111/all.14338
Abstract
Background Dupilumab is an anti‐IL‐4Rα antibody used in the treatment of patients with moderate‐to‐severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD. Methods This multicentric, prospective, observational, real‐life study, included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Efficacy outcomes regarding AD, PAR and PAA, were collected at baseline and 16 weeks. Safety was also assessed. Results We enrolled 123 patients with msAD. Between baseline and 16 weeks of treatment, the following measurements decreased statistically significantly: Eczema Area and Severity Index, SCOring AD, Patient‐Oriented Eczema Measure, pruritus score, sleep score, Dermatology Life Quality Index and IgE. Dupilumab treatment in patients with comorbid PAR (n=41) was associated with significant improvements in PAR disease control (measured using a Rhinitis Control Scoring System) and in PAR Quality of life (QoL) (measured using the Rhinoconjunctivitis QoL Questionnaire scores). In 32 patients with comorbid PAA, dupilumab significantly improved PAA control (measured using the Asthma Control Test and five‐item Asthma Control Questionnaire scores) and disease‐related QoL (measured using the Asthma QoL Questionnaire scores). Thirty‐five patients (28.5%) developed conjunctivitis during the study period. Conclusion These results support the benefits of dupilumab for adult patients with PAR and/or PAA associated with msAD.This publication has 38 references indexed in Scilit:
- Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adultsAnnals of Allergy, Asthma & Immunology, 2018
- Atopic dermatitis in US adultsAnnals of Allergy, Asthma & Immunology, 2018
- Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disordersClinics in Dermatology, 2017
- Multidisciplinary interventions in the management of atopic dermatitisJournal of Allergy and Clinical Immunology, 2016
- Update on Epidemiology, Diagnosis, and Disease Course of Atopic DermatitisSeminars in Cutaneous Medicine and Surgery, 2016
- Atopic dermatitis and the atopic march revisitedAllergy, 2013
- From atopic dermatitis to asthma: the atopic marchAnnals of Allergy, Asthma & Immunology, 2010
- Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveysThe Lancet, 2006
- Natural history of atopic dermatitis and its relationship to serum total immunoglobulin E in a population‐based birth cohort studyPediatric Allergy and Immunology, 2004
- Epidemiology of atopic dermatitisClinical and Experimental Dermatology, 2000